Brief: Axovant Signs Three-Year Clinical Supply Agreement With Oxford Biomedica For Manufacturing And Supply Of Axo-Lenti-Pd

Sio Gene Therapies

31/07/2020 11:50

July 31 (Reuters) - Axovant Gene Therapies Ltd  AXGT.O :
    * AXOVANT SIGNS THREE-YEAR CLINICAL SUPPLY AGREEMENT WITH
OXFORD
BIOMEDICA FOR MANUFACTURING AND SUPPLY OF AXO-LENTI-PD
    * AXOVANT GENE THERAPIES LTD - SIGNED A THREE-YEAR CLINICAL
SUPPLY
AGREEMENT  WITH OXFORD BIOMEDICA
    * AXOVANT GENE THERAPIES LTD - OXFORD BIOMEDICA WILL
MANUFACTURE
GMP BATCHES FOR AXOVANT TO SUPPORT ONGOING AND FUTURE CLINICAL
DEVELOPMENT OF AXO-LENTI-PD
    * AXOVANT GENE THERAPIES LTD - AXOVANT IS CURRENTLY
CONDUCTING
PHASE 2 SUNRISE-PD TRIAL WITH AXO-LENTI-PD
    * AXOVANT GENE THERAPIES - OXFORD BIOMEDICA EXPECTS TO
MANUFACTURE
AXO-LENTI-PD IN COMMERCIAL-SCALE GMP MANUFACTURING FACILITIES
INCLUDING OXBOX IN UK

Source text for Eikon:  ID:nGNXbGknnf 
Further company coverage:  AXGT.O 

 ((Reuters.Briefs@thomsonreuters.com;))